Cited 0 times in
Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.date.accessioned | 2022-08-05T06:06:53Z | - |
dc.date.available | 2022-08-05T06:06:53Z | - |
dc.date.issued | 2018-03 | - |
dc.identifier.issn | 2468-4562 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/188875 | - |
dc.description.abstract | Background: Fourth-line therapy (4LT) in the treatment of metastatic renal cell carcinoma (mRCC) varies significantly due to the lack of data and recommendations to guide treatment decisions. Objective: To evaluate the use and efficacy of 4LT in mRCC patients. Methods: The International mRCC Database Consortium (IMDC) dataset was used to identify patients with mRCC treated with 4LT. This is a multicenter, retrospective cohort study. Overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier curves. Patients were evaluated for overall response. The six prognostic variables included in the IMDC prognostic model were used to stratify patients into favorable-, intermediate- and poor-risk groups. Exploratory analyses were performed examining the elderly (>70 years old) and non-clear cell RCC subgroups. Proportional hazards regression modelling was performed adjusting these covariates by IMDC criteria measured at initiation of 4th line therapy. Results: 7498 patients were treated with first line targeted therapy and out of these 594 (7.9%) received 4LT. Everolimus was the most frequently used 4LT (16.8%). Sorafenib, axitinib, pazopanib, sunitinib and clinical trial drugs were also used in >10% of patients. The OS of patients on any 4LT was 12.8 months, with a PFS of 4.4 months. The overall response rate (ORR) was 13.7%. Favorable-risk patients using IMDC criteria (5%) displayed an OS of 23.1 months, intermediate-risk patients (66%) had an OS of 13.8 months and poor-risk patients (29%) had an OS of 7.8 (p < 0.0001) months. Age >70 years and non-clear cell histology did not impact OS. Our study is limited by its retrospective design. Conclusions: 4LT use appears to have activity in mRCC patients. The IMDC continues to be of prognostic value in the fourth-line setting for OS. This study helps to set a benchmark for response rate and survival for which clinical trials can plan sample size calculations and aim to improve upon. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | IOS Press | - |
dc.relation.isPartOf | KIDNEY CANCER(Kidney Cancer) | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Stukalin, Igor | - |
dc.contributor.googleauthor | Wells, J. Connor | - |
dc.contributor.googleauthor | Fraccon, Anna | - |
dc.contributor.googleauthor | Pasini, Felice | - |
dc.contributor.googleauthor | Porta, Camillo | - |
dc.contributor.googleauthor | Lalani, Aly-Khan A. | - |
dc.contributor.googleauthor | Srinivas, Sandy | - |
dc.contributor.googleauthor | Bowman, I. Alex | - |
dc.contributor.googleauthor | Brugarolas, James | - |
dc.contributor.googleauthor | Lee, Jae-Lyun | - |
dc.contributor.googleauthor | Donskov, Frede | - |
dc.contributor.googleauthor | Beuselinck, Benoit | - |
dc.contributor.googleauthor | Bamias, Aristotelis | - |
dc.contributor.googleauthor | Rini, Brian I. | - |
dc.contributor.googleauthor | Sim, Hao-Wen | - |
dc.contributor.googleauthor | Agarwal, Neeraj | - |
dc.contributor.googleauthor | Rha, Sun-Young | - |
dc.contributor.googleauthor | Kanesvaran, Ravindran | - |
dc.contributor.googleauthor | Choueiri, Toni K. | - |
dc.contributor.googleauthor | Heng, Daniel Y.C. | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J04221 | - |
dc.identifier.eissn | 2468-4570 | - |
dc.subject.keyword | Metastatic renal cell carcinoma | - |
dc.subject.keyword | fourth line therapy | - |
dc.subject.keyword | targeted therapy | - |
dc.subject.keyword | checkpoint inhibitors | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | 라선영 | - |
dc.citation.volume | 2 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 31 | - |
dc.citation.endPage | 36 | - |
dc.identifier.bibliographicCitation | KIDNEY CANCER(Kidney Cancer), Vol.2(1) : 31-36, 2018-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.